Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1. A herpesvirus family member, CMV is spread through body fluids.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

pharmaphorum

JANUARY 21, 2022

A third dose of vaccine has been shown to effectively neutralise the Omicron variant of covid-19, according to researchers. Research led by UCLH, UCL and the Francis Crick Institute found that the booster dose successfully stimulates antibody levels that neutralise Omicron. Overall, antibody levels were nearly 2.5

Antibody 114

Antibody Vaccination Vaccine Genotype 114

Drug Discovery World

FEBRUARY 27, 2024

New studies have demonstrated that Vaxxinity’s vaccine VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease.

Vaccination 104

Vaccination Vaccine Antibody Clinical Trials 104

Medical Xpress

DECEMBER 6, 2022

Nearly three years into the pandemic, many of us now carry antibodies against the virus—due to an infection or two, a few doses of mRNA vaccine, or a round of monoclonal-antibody treatment.

Antibody 98

Antibody Vaccination Vaccine Immune Response 98

BioSpace

NOVEMBER 8, 2021

AstraZeneca announced its plans to create a new, separate division for vaccines and antibody therapies, specifically its COVID-19 vaccine developed with the University of Oxford and other COVID-19 antibody treatments.

Antibody 103

Antibody Vaccination Vaccine Development 103

Pharmaceutical Technology

AUGUST 23, 2023

The programme is part of US BARDA’s ‘Project NextGen’ to develop countermeasures against Covid-19 current and future strains.

Development 130

Development Antibody Vaccination Vaccine 130

Drug Discovery World

AUGUST 25, 2023

A new study at UTHealth Houston in the US has found that several routine vaccinations are linked to a significant reduced risk of Alzheimer’s disease (AD). In 2022, Schulz’s team also found that people who received at least one influenza vaccine were 40% less likely than their unvaccinated peers to develop AD.

Antibody 52

Antibody Vaccination Vaccine Protein 52

Pharmaceutical Technology

SEPTEMBER 15, 2022

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccination 272

Vaccination Vaccine Sales Generic Drugs 272

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Flavivirus vaccine components. Sanofi is one of the leading patent filers for Flavivirus vaccine components.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

Pharmaceutical Technology

JUNE 20, 2023

The World Health Organisation (WHO) has granted an emergency use listing (EUL) to SK bioscience’s Covid-19 vaccine, SKYCovione. SKYCovione is a self-assembled nanoparticle vaccine and the 12th Covid-19 vaccine to receive a EUL from the regulator.

Vaccination 363

Vaccination Vaccine Protein Clinical Trials 363

Pharmaceutical Technology

AUGUST 24, 2022

5 Omicron-targeting bivalent booster vaccine for Covid-19. The submission is made for a 50µg booster dose of the vaccine for usage in adults aged 18 years and above. As against a 50µg booster dose of mRNA-1273 in priorly uninfected subjects, mRNA-1273.214 demonstrated superior neutralising antibody response against Omicron BA.1

Vaccination 130

Vaccination Vaccine Gene Therapy Antibody 130

XTalks

JULY 25, 2023

Emergent BioSolutions, a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland, has achieved a significant milestone with the approval of its Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted) vaccine by the US Food and Drug Administration (FDA). What Is Anthrax? How Does Cyfendus Work?

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

BioPharma Reporter

AUGUST 2, 2021

The mRNA vaccine developed by Pfizer and BioNTech generates far higher levels of antibodies against the coronavirus than Sinovacâs inactivated virus prophylactic, according to a study.

Antibody 98

Antibody Vaccination Vaccine Development 98

Drug Discovery World

MARCH 5, 2024

Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored ‘dark side’ of the neuraminidase (NA) protein head.

Antibody 59

Antibody Protein Vaccination Vaccine 59

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

pharmaphorum

MARCH 31, 2021

In the latest episode of the podcast Dominic Tyer speaks with GlaxoSmithKline’s Philip Cruz about the discovery and commercialisation of new vaccines in the light of the pandemic. They also talk about the impact anti-vaxx misinformation has had on vaccine uptake in recent years and what impact COVID has had on that.

Vaccination 98

Vaccination Vaccine Development Antibody 98

BioPharma Reporter

JANUARY 17, 2022

Vir Biotechnology and the Bill & Melinda Gates Foundation have partnered up to develop broadly neutralizing antibodies designed to provide a âvaccinal effectâ for the treatment of HIV and prevention of malaria.

Antibody 143

Antibody Development Vaccination Vaccine 143

XTalks

FEBRUARY 21, 2024

This episode features an interview with Amir Reichman, CEO of Scinai Immunotherapeutics , a biopharma company focused on developing cutting-edge biological treatments within the inflammation and immunology (I&I) sector, with a primary focus on addressing autoimmune and infectious diseases.

Life Science 105

Life Science Development Antibody Vaccination 105

Medical Xpress

JANUARY 4, 2023

Myocarditis, a condition in which the heart muscle becomes inflamed, is a rare complication that can occur after mRNA COVID vaccination. It's estimated that roughly 18 cases occur in every 1 million vaccine doses administered, making it so rare that it is challenging to find cases to investigate.

Immune Response 91

Immune Response Protein Vaccination Vaccine 91

pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front.

Vaccination 134

Vaccination Vaccine Clinical Trials Clinical Trials 134

Drug Discovery World

MARCH 24, 2023

SpyBiotech, a UK-based biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from the Bill & Melinda Gates Foundation to further develop its novel SpyVector platform.

Vaccination 52

Vaccination Vaccine Development Genetics 52

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus. Other efforts to develop a nasally-delivered COVID-19 vaccine have met with greater success.

Vaccination 115

Vaccination Vaccine Immune Response Development 115

BioSpace

OCTOBER 26, 2021

Nuravax is developing a vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins associated with both AD and Parkinson's disease.

Vaccination 131

Vaccination Vaccine Protein Antibody 131

Pharmaceutical Technology

AUGUST 23, 2022

5-adapted bivalent vaccine for Covid-19 in people aged 12 years and above. 1-adapted vaccine. The FDA also sought the vaccine’s pre-clinical and manufacturing data for addressing the SARS-CoV-2 virus’ evolution. 5-adapted bivalent vaccine will be made readily available for shipping. 5-adapted bivalent vaccine.

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

Drug Discovery World

OCTOBER 13, 2023

Researchers at Harvard Medical School (HMS) in the US and the University of Oxford have developed a new artificial intelligence (AI) tool named EVEscape that can predict new viral variants before they emerge. Another important application of EVEscape would be to evaluate vaccines and therapies against current and future viral variants.

Vaccination 105

Vaccination Vaccine Immune Response Scientist 105

Scienmag

JULY 19, 2022

Yale scientists have developed a novel Omicron-specific mRNA vaccine that offers superior immune protection against two viral subvariants than standard mRNA vaccines. The new vaccine, called Omnivax, increased neutralizing antibody response against the BA.1 New Haven, Conn. The […].

Vaccination 61

Vaccination Vaccine Development Antibody 61

Scienmag

JANUARY 4, 2021

In advance of public vaccination, a quick and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies, the molecules that aid in protection against the virus. Credit: UAB BIRMINGHAM, Ala.

Vaccination 98

Vaccination Vaccine Antibody Development 98

Drug Discovery World

FEBRUARY 19, 2024

Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).

Vaccination 52

Vaccination Vaccine Immune Response RNA 52

Drug Discovery World

OCTOBER 11, 2023

MinervaX, a Danish biotechnology company developing a novel, prophylactic vaccine against Group B streptococcus (GBS), has announced the completion of €54 million upsized financing. GBS is a leading cause of life-threatening infections in newborns as well as adverse pregnancy outcomes such as preterm delivery and stillbirths.

Vaccination 59

Vaccination Vaccine Clinical Trials Clinical Trials 59

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccination 277

Vaccination Vaccine Immune Response Antibody 277

XTalks

MARCH 1, 2021

(NYSE: PFE ) and BioNTech SE (Nasdaq: BNTX ) have announced that they are beginning a trial to evaluate the safety and efficacy of a third booster dose for their COVID-19 vaccine (BNT162b2), as well as new vaccine variants. Related: Could Pfizer and BioNTech’s COVID-19 Vaccine be Stored at Standard Freezer Temperatures?

Vaccination 111

Vaccination Vaccine Development In-Vitro 111

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. Antibodies cover the pathogen of the virus and neutralise it.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

pharmaphorum

JANUARY 13, 2021

IO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) to further develop its cancer vaccine technology that has boosted efficacy of PD-1 immunotherapy in early trials. The post IO Biotech raises $155m to develop breakthrough cancer vaccine appeared first on.

Vaccination 95

Vaccination Vaccine Development In-Vivo 95

Drug Discovery World

JULY 28, 2022

Researchers at the Francis Crick Institute in the UK, have shown that a specific area of the SARS-CoV-2 spike protein is a promising target for a pan-coronavirus vaccine that could offer some protection against new virus variants, common colds, and help prepare for future pandemics.

Vaccination 52

Vaccination Vaccine Development Protein 52

Scienmag

FEBRUARY 4, 2022

million people, with no vaccine in sight. However, a new study by researchers at The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, takes a promising step in the direction of developing […]. PHILADELPHIA — (Feb.

Vaccination 81

Vaccination Vaccine Development Research 81